Summary:
The use of peripheral blood stem cells (PBSC) for allogeneic transplants in adults has greatly increased. This trend is reflected in pediatrics, where healthy children increasingly are donating PBSC or donor lymphocyte infusion (DLI) via apheresis for use by ill siblings. There is a potential concern that the risks of PBSC collection may differ for pediatric donors. However, no large studies have assessed safety issues in this population. To address this need, we reviewed 218 (213 PBSC, five DLI) collections in 201 normal pediatric donors (8 months to 17 years, median 11.8 years) at 22 institutions in the Pediatric Blood and Marrow Transplant Consortium. Donors received a median of 4 days of growth factor, and mean collection yield was 9.1 Â 10 6 CD34 þ cells/kg recipient weight. Younger age, days of apheresis, and male gender predicted increased yield of CD34 þ cells/kg donor weight. Growth factor-induced pain was mild and reported in less than 15% of patients. Most donors o20 kg (23/25, 92%) required PRBC priming of the apheresis machine. This experience with over 200 collections demonstrates that PBSC collection is safe in normal pediatric donors and desired CD34 cell yields are easily achieved. Younger children utilize more medical resources and children o20 kg usually require a single blood product exposure. The use of cytokine-mobilized peripheral blood stem cells (PBSC) from HLA-matched related donors is well established in adults, offering more rapid myeloid and platelet engraftment and less early transplant-related morbidity and mortality. 1, 2 Outcome has been superior for adult patients with advanced and high-risk leukemias, but PBSC increases the risk of chronic graft-versus-host disease. 2, 3 Pediatric transplant patients have traditionally differed from adult BMT recipients, with large percentages of high-risk leukemia, less transplant-related mortality for matched sibling transplantation, and less chronic graft-versus-host disease. 4, 5 Although studies from centers in Spain, Japan, and America have shown successful outcomes in small numbers of pediatric patients receiving matched sibling allogeneic PBSC, [6] [7] [8] [9] large trials designed to define pediatric populations that could benefit from PBSC as a stem cell source have yet to be performed. 10 An impediment to further evaluation of PBSC in pediatrics is a lack of safety data regarding pediatric sibling donors. 11 There is published experience in the collection of PBSC in younger cancer patients for autologous use, [12] [13] [14] [15] but only a limited number of studies with small patient numbers address normal pediatric donor safety and collection efficacy. [6] [7] [8] 16 Most pediatric donors are close in age to their recipient siblings and therefore young and small. Younger children need central lines placed more often and may be at increased risk with the procedure. 17 In addition, the side-effect profile associated with use of growth factors in and apheresis of younger donors has not been well described. Finally, efficacy data and information regarding resource utilization for this young donor pool undergoing this procedure are limited. In order to examine these issues in a large group of healthy pediatric PBSC donors, we gathered data regarding 218 collections performed on 201 normal pediatric allogeneic PBSC and donor lymphocyte infusion (DLI) donors from 22 transplant centers in the Pediatric Blood and Marrow Transplant Consortium (PBMTC). This extensive experience showed an excellent safety and efficacy profile, even in very young children, with improved collection efficiency in the youngest group of donors.
Methods
A total of 22 PBMTC centers (listed in Appendix A1) who had collected PBSC or DLI from normal pediatric donors agreed to participate in this retrospective review. Other centers in the PBMTC either had not performed this procedure or chose not to participate. IRB approval or exemption was obtained at each center and central reviewers were blinded to specific patient identifiers in accordance with United States HIPPA regulations. Data were gathered on procedures performed between 1996 and 2003 by means of a detailed questionnaire that included demographics on the donor and recipient limited to age, gender, and weight. Also, details regarding growth factor administration, vascular access, the apheresis procedure, and specific complications of these interventions were collected. The questionnaire used parameters measurable by chart review that could be applied to the common toxicity (CTC) criteria in order to assess donor adverse events. Centers reported between 1 and 48 patients with a median number of 6 and a mean of 10. Because the focus of our retrospective analysis was donor safety and efficacy of collection, recipient outcomes such as survival and engraftment were not assessed.
To address reporting bias, each survey included documentation of whether donors were enrolled on an IRB-approved protocol that included reporting of their toxicities. In all age groups, approximately 50% of patients were treated on protocols requiring donor toxicity reporting (Table 1 ). To assess whether the incidence of reported toxicities was similar between centers required to report donor toxicity data to their IRB and centers not required to report these data, we compared the number of events in four areas where hard laboratory data were not available and medical record documentation or IRB reporting was necessary. These included bleeding at any time, pain due to CVL placement, pain secondary to G-CSF or GM-CSF therapy, and symptomatic hypocalemia. No difference was noted between the two groups, with 27 and 28 events reported from centers with and without donor IRB reporting requirements, respectively.
Statistical analysis
To assess whether risks were dependent upon age, we analyzed the children in three age groups: infant/preschool (0-6 years of age), early school age (7-12 years), and adolescents (12-17 years). For significance testing of differences between age groups in crosstables, w 2 analysis, the Cohran-Mantel-Haenszel statistic, or analysis of variance was used where appropriate. A univariate analysis of the prognostic effect of each predictor (donor weight, donor age, donor gender, days of apheresis, days of growth factor) on CD34 þ yield per kilogram donor weight was conducted. A multivariate analysis of the above predictors and their interactions using a forward selection method model was performed. In the final model, all variables with a P-value of 0.10 or below in either the univariate analysis or multivariate selection model were included. Table 1 shows demographic information regarding donors and recipients. Of the procedures reported, 56% were performed on donors aged 12 and under, with 39 collections from donors less than 7 years old. Recipients were more commonly male, but donors were equally represented by gender, and donor-recipient gender match-ups did not vary with age groups (data not shown). Weights of donors and recipients varied, but on average were similar between donors and recipients except in donors aged 6 and under, where recipients were on average larger than their donors.
Results

Patient characteristics
Use of apheresis catheters
Review of our study population revealed that younger pediatric donors required central catheter placement for collection more often than older donors (Table 2) . It is to be noted that one-third of donors between ages 7 and 12 were successfully collected using peripheral access. A difference in utilization of sedation for line placement was noted, with all of the younger donor group requiring sedation compared to only 14% of older patients. Whether conscious sedation or general anesthesia was used at any age was most closely associated with the discipline of the practitioner who placed the catheter: surgeons used general anesthesia 78% of the time, while interventional radiologists and intensivists chose conscious sedation 75 and 83% of the time, respectively. Complications of catheter placement were limited and mild ( Table 2) . Pain of any kind was reported in 17-35% of patients, depending on age category, with about half of those reporting pain requiring brief use of narcotic medication. One patient had poor blood draw after placement of a subclavian line. A chest X-ray revealed what was thought to be a small hemothorax. The line was removed and the collection completed without further complications using a femoral catheter. No patients experienced pneumothorax, pulmonary embolus, or other severe complications. In addition, no catheter-related infections were reported.
Complications of growth factor administration and apheresis
More than 95% of donors in all age categories received G-CSF alone. The mean dose given in all groups varied from 10 to 11 mg/kg/day, the most common dosage being 10 mg/ kg/day given subcutaneously as a single daily dose or divided b.i.d. Donors were treated on average just over 4 days with doses ranging from 5 to 27 mg/kg/day. A small fraction of patients received GM-CSF at 5 mg/kg/day with or without G-CSF.
In spite of these high doses of growth factors, bone pain or myalgias was reported in only 11-15% of older children and was not reported in our youngest group, with a statistically significant increase of reported pain in older donors (P ¼ 0.02). Narcotic usage for G-CSF-related pain occurred in only one teenage donor (Table 3 ) and no pain exceeded CTC grade 2.
Criteria reported for completing apheresis was most frequently a minimum target CD34 þ cell count/kg recipient body weight. From centers reporting the use of such a target, the cell count targeted ranged from 2 to 10 Â 10 6 CD34 þ cells/kg. Several centers collected based on blood volumes with targets varying from 4 to 6 volumes. Complications associated with the apheresis procedure itself were rare, with two teenage donors experiencing minimal local bleeding at their line sites (Table 3 , maximum CTC grade 1).
Acid citrate dextrose-A (ACD-A) solution is utilized in apheresis as an anticoagulant. Hypocalcemia is a toxicity of citrate administration 18, 19 and is thought to be more common in pediatric patients receiving citrate than adults. 12, 20 Hypocalcemia was screened for in 77% of the donors and measured in 4% (three with ionized Ca 2 þ o0.8 mmol/l (CTC grade 4), one between 0.8 and 0.9 mmol/l (CTC grade 3), and three between 0.9 and 1.0 mmol/l (CTC grade 2)). Symptoms thought to be caused by hypocalcemia (lip smacking, abdominal pain, tingling of lips, tongue, and fingers) occurred in 6% of patients (Table 3) . This low incidence of reported hypocalcemia occurred in the context of 67% of apheresis procedures performed including some type of prophylactic calcium supplementation, ranging from a calcium-rich diet to an intravenous calcium infusion. All measured or symptomatic hypocalcemia was treated with calcium administration and resolved quickly. No tetany was observed. 
CD34 þ cell yield
The average number of apheresis procedures performed per harvest was 1.4 for all age groups. Harvests in these young donors yielded on average between 7 and 10 Â 10 6 of CD34 þ cells/kg recipient or donor weight, with the average yield per single apheresis procedure ranging from 6 to 8 Â 10 6 /kg measured by donor weight (see Table 4 ). Donors in the youngest age cohort yielded more per kilogram donor weight than older donors (P ¼ 0.02). Male donors yielded more cells than female donors, but this difference did not meet significance, with a Pvalue of 0.06. In order to assess determinants of collection efficacy, we analyzed these data using a multivariate model. Donor age and weight are inextricably linked. Both donor age and donor weight were considered separately and together in the model. Donor age produced a better fit for the data than donor weight. Taking donor age, sex, and days of growth factor treatment into account, the multivariate analysis found that days of growth factor and donor age were significant with P-values of 0.003 and 0.007, respectively, even when adjusted for days of apheresis. Again, adjusted for days of apheresis, gender of the donor approached but did not meet significance at P ¼ 0.07.
Blood product exposure
The disparity between patient blood volume and extracorporeal volume in the apheresis circuit results in a risk of significant dilution of hematocrit during an apheresis procedure in very young children. Thus, it is an established practice in most centers to prime the apheresis machine with red cells for these patients. In our cohort, 92% of donors under 20 kg required PRBC priming of the apheresis circuit, using 0.5-1 unit/day of collection, while only 6% of children between 20 and 30 kg were exposed to red cells for this reason. Some centers returned autologous platelet-rich plasma if the donor's platelet level fell and subsequent days of collection were planned. This occurred in 3/80 (4%) in the 7-to 12-year-old group and 8/94 (9%) in the 13-to 17-year olds. Table 5 outlines selected measures of resource utilization. Younger donors were more likely to stay overnight, have the apheresis procedure performed in an Intensive Care Unit, and have a second or extended anesthesia. The major reason reported for overnight stays was 'routine observation', with the second most common reason being Table 3 Complications of cytokine administration and apheresis monitoring of a femoral line (data not shown). Several centers reported a decrease in routine overnight stays as they became more experienced with the procedure.
Resource utilization
Discussion
Over the past several years, the use of cytokine-mobilized PBSCs has increased in pediatrics. Data from the PBMTC, representing over 70 transplant centers in the United States and Canada, have shown a steady increase in use of matched sibling PBSC (Figure 1 ), reaching 26% of the matched sibling allogeneic procedures performed in 2002.
In spite of the increase in this practice, studies assessing safety in normal pediatric donors have reported limited data on a small number of patients. de La Rubia et al 16 described donor complications in 61 pediatric donors harvested by the Spanish cooperative group. They noted fewer side effects in pediatric donors compared to an adult cohort (41 vs 71%). Kawano et al 8 described side effects in 19 pediatric PBSC donors in more detail suggesting an agerelated difference in pain symptoms secondary to G-CSF. Of their 19 donors, 0/9 children under 10 years experienced discomfort, while 5/10 children aged 410 years complained of mild headache or fatigue. 8 The PBSCT Study group of Japan published a study expanding the Kawano experience, which focused mostly on outcome of transplant but briefly described side effects of 57 donors between the age of 9 months and 24 years. Bone pain was described in 17.5% and headache in 5.3% during G-CSF therapy. 6 Our experience expands and clarifies toxicities experienced by pediatric donors and shows a lower incidence of growth factor-related side effects in the very youngest pediatric patients (see Table 3 ). Prospective studies in adults report a higher incidence of pain and other cytokinerelated side effects than we report (up to 60% receiving 12 mg/kg/day experienced grade 2-3 NCI CTC side effects). 21 While our data showing less pain in young children are consistent with the Spanish cooperative group and the Japanese experience, only large prospective trials tracking donor safety could more definitively ascertain whether the true incidence of pain and side effects is lower in children.
Theoretical concerns exist about short-term growth factor therapy potentially increasing the long-term risk of leukemia and thus increasing the risk of PBSC donation for normal donors. Experience with G-CSF therapy in pediatric patients with other diseases combined with longterm follow-up data from adult PBSC donors gives insight into this risk. In spite of thousands of patient years of cytokine therapy, no patients with cyclic or idiopathic neutropenia treated with G-CSF and registered in the Severe Chronic Neutropenia International Registry have been reported with progression to cancer. 22 Approximately 10% of patients in that registry with congenital neutropenia (Kostmann syndrome) who have been treated with G-CSF progressed to MDS or AML, but this rate is similar to the rate of progression without G-CSF therapy and thus is likely to be related to the underlying disease, rather than the growth factor exposure. A similar lack of evidence of long-term adverse hematologic effects has been noted in a 2-year follow-up of neonates treated with G-CSF for sepsis. 23 Studies in normal adult PBSC donors have shown no late effects associated with short-term G-CSF therapy with 3-6 years of follow-up. 24, 25 Other studies in normal donors showed no lingering DNA instability 2-4 weeks after cytokine use and normal T, B, and NK cell counts a year after donation. 26, 27 Recently, a report of AML developing in a 62-year-old female patient 14 months after G-CSF-primed PBSC donation (for a brother with multiple myeloma) was published. 28 Whether G-CSF therapy contributed to the development of this cancer is unknown, but future studies should carefully track donors and report any similar incidents. Taken together, the evidence available at this point suggests that the risk of major late toxicities secondary to short-term administration of G-CSF is at most minimal.
Our data set analysis confirms the trend seen in other, smaller studies of autologous stem cell collection in children, indicating that small size is no barrier to apheresis or successful collection of large numbers of PBSC. Indeed, our youngest age cohort provided the largest number of CD34 þ cells, expressed in terms of either cells/donor weight or cells/recipient weight. Marrow cellularity and total area of marrow production, such as sternum and long bones, decline with age, so the observation of increasing yields with younger age, although new, is perhaps not surprising.
This large, restrospective pediatric experience gives insights that could lead to safer, more cost-effective practice of this procedure. First, one-third of children aged 7-12 underwent apheresis with peripheral catheters, suggesting that centers should carefully evaluate for this possibility, even in younger donors. Second, even in the youngest group, the majority of donors had safe central-line placement using conscious sedation rather than general anesthesia, and second anesthesias are generally not needed for line removal. Finally, many centers performed harvests without overnight or ICU stays, but this particular cost saving is dependent upon the comfort level and support available at any given center.
One of the chief concerns with this study is the finding that donors weighing less than 20 kg were almost universally exposed to blood products. It is to be noted that only two patients above 20 kg needed a blood prime, suggesting that patients above this weight can avoid exposure to blood products in most cases. Japanese studies using normal donors less than 20 kg mandated two or three 5-10 ml/kg autologous blood draws in sequential weeks prior to the PBSC harvest along with supplemental iron therapy. With this approach, they used only autologous blood priming for all of their small donors. 8 Given the near-universal practice of blood priming of the apheresis circuit in children less than 20 kg, if future studies are considered that include this population, approaches that minimize or eliminate the risk of blood product exposure for these small pediatric donors should be utilized.
This study is the largest and most comprehensive look into the efficacy and donor safety profile of pediatric allogeneic PBSC collection, providing a safety baseline useful to future studies utilizing apheresis of normal donors for PBSC collection. Because half of the patients were enrolled in IRB protocols mandating reporting of donor events, this portion of the data set may be less subject to the potential bias of under-reporting associated with a retrospective study, although we noted no difference in the incidence of events reported between centers with and without IRB mandated reporting of donor toxicities. That said, it is likely that grade 1 and 2 adverse events such as mild pain are under-reported. Future studies involving pediatric PBSC should carefully track donor safety prospectively to insure that rare significant adverse events are not missed.
